Business Wire

NV-KALRAY

21.5.2024 14:07:34 CEST | Business Wire | Press release

Share
Kalray Debuts Ngenea® for AI, a Data Acceleration Platform for GenAI and RAG

Kalray (Euronext Growth Paris: ALKAL), a technology innovator building software and hardware solutions that accelerate data-intensive workflows, announced Ngenea® for AI, a new edition of its Kalray Data Acceleration Platform specifically fine-tuned for AI data pipelines. As AI demands new ways to ingest and access massive volumes of data, Ngenea for AI helps teams speed up performance, simplify data management and open their data assets to new AI-powered use cases.

Ngenea for AI is the companion to two Ngenea editions for Media & Entertainment and HPC customers, respectively. The new Ngenea for AI empowers AI innovators to speed up their ingest performance and access their unstructured data from a unified, global name space. Kalray debuted Ngenea for AI at Dell Technologies World 2024 in Las Vegas today, where the software’s performance on Dell servers is being showcased in the Kalray Booth #1026.

The generative AI (GenAI) market is predicted to see 42% compound annual growth rate (CAGR) across the next 10 years into a $1.3 trillion space, from just $40 billion in 2022 (Bloomberg Intelligence). Yet innovative AI constructs such as large language models (LLMs) and Retrieval-Augmented Generation (RAG), and applications including Smart Vision and GenAI, are challenging the ability of IT systems to move data to and from their massive data stores.

ENABLING GENAI AND RAG

Ngenea for AI adds data indexing and search capabilities, which users can leverage to feed any data to Smart Vision, GenAI and RAG applications effortlessly. The new offering enables AI customers to fully harness their existing assets when deploying GenAI applications, regardless of where the data is stored. These GenAI and RAG capabilities simplify and automate what would otherwise be a complex workflow from a data management aspect.

”Fast AI processing is mission-critical to our business of detecting railcar anomalies before they lead to breakdowns or derailments. With Ngenea deployed along with Dell Technologies products, Duos achieved a 120x performance boost on our Railcar Inspection Portal (RIP®) solution, and an 8x increase in inspection accuracy. Working with Kalray helped us put railroads at the forefront of innovation,” said Jeff Necciai, chief technology officer of Duos Technologies.

HIGH-PERFORMANCE STORAGE TIER TO FEED GPUS EFFORTLESSLY

The Ngenea for AI platform also incorporates a high-performance storage tier for the most data-intensive AI workloads. The tier is powered by a proven high-performance parallel file system that can easily manage petabytes of data and billions of files – whether data live on the edge, in the cloud, or on premises. This allows customers and partners to maximize the value of their GPU investment, without rip-and-replace deployments.

With Ngenea, AI innovators:

  • Accelerate AI workflows by optimizing AI data pipelines and enhancing the overall speed and efficiency of AI operations.
  • Boost the AI model performance by feeding data to GPUs faster, allowing for quicker computations and accelerated insights.
  • Gain advanced data indexing capabilities that enable Generative AI and RAG applications to deliver more refined search functionalities, enabling more effective queries and a more strategic utilization of AI models.
  • Facilitate a controlled and optimized connection between company data and a suite of third-party AI-powered tools, ensuring seamless integration and data synergy.

Optional hardware acceleration via Kalray’s DPUs including the TURBOCARD4 (TC4) allows parallel processing in an asynchronous way for ultra-demanding workflows, via a complementary architecture to GPUs.

Even with the tremendous commitment that C-suite leaders are making to AI, very few CIOs have the sizable budgets required to deploy a new system solely for an AI rollout,” said Scott Sinclair, practice director, infrastructure, and modernization, at the Enterprise Strategy Group TM. “Innovative use cases that enable enterprises to leverage their existing infrastructure and still deploy novel AI applications address a sizable untapped need in the market.”

AI TOOLKIT FOR EASY INTEGRATION

Ngenea for AI includes an AI Toolkit that Kalray partners can use for easy integration of their applications with Ngenea. For example, when integrating Ngenea with Perifery Vision AI, users can intuitively search for historical content across a vast amount of data on locations, types, and collections.

Traditional data centers weren’t built for massive data sets found in AI workloads – or to process these workloads rapidly and efficiently,“ said Eric Baissus, CEO of Kalray. “Kalray’s Ngenea for AI is the data acceleration platform for the AI age – software that elevates performance on existing servers and storage and provides toolkits that streamline application integration. With our software, enterprises and service providers can feed GPUs effortlessly - optimizing data movement and orchestration as the foundation of their infrastructure - so that AI genuinely delivers a competitive edge.“

The Ngenea for AI platform joins two other Ngenea editions that streamline application integration for specific use cases: Ngenea for HPC – providing scratch storage, or storage for temporary user data, and Ngenea for Media & Entertainment – to accelerate post-production workflows.

Ngenea for AI is available today from Dell, from Kalray and select partners. For more information visit here.

ABOUT KALRAY

Kalray is a technology innovator specializing in software and hardware solutions to accelerate data-intensive workflows in Media & Entertainment, High-Performance Computing, and Artificial Intelligence. Our comprehensive product range features Ngenea, a leading data acceleration platform, as well as accelerated data processing cards for storage and compute.

With Kalray solutions, customers can scale their infrastructures to efficiently meet the performance and capacity needs of data-intensive tasks, all without being tied to specific data formats or vendors.

Founded in 2008 as a spin-off from the French CEA research lab, Kalray has corporate and financial backing from notable investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors, and Bpifrance. Committed to innovation and excellence, we strive to deliver value to our customers, developers, and the planet through technology and expertise.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240521509685/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye